| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 217.0 | 174.4 | 168.9 |
| Other income | 1.9 | 1.2 | 1.9 |
| Total income | 218.9 | 175.6 | 170.7 |
| Profit before exceptional items & tax | 10.8 | 7.5 | 4.2 |
| Profit before tax | 10.8 | 7.5 | 4.2 |
| Net profit | 8.1 | 5.9 | 4.2 |
| Operating margin | 4.9% | 4.3% | 2.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +92.90% |
|---|---|
| Net profit, quarter on quarter | +37.30% |
| Revenue, year on year | +28.50% |
| Operating profit, year on year | +287.00% |
| Operating profit, quarter on quarter | +41.30% |
BSE results filing, NSE: SUDARSHAN. Figures extracted from the filing.
Sudarshan Pharma Industries Ltd: key numbers
- Share price
- ₹36.95
- Market cap
- ₹889.2 Cr
- Revenue (annual)
- ₹703.1 Cr
- Net profit (annual)
- ₹23.30 Cr
- P/E (TTM)
- 38.2×Sector 34.1×
- Promoter holding
- 57.81%-1.12% QoQ
- FII holding
- 21.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudarshan Pharma Industries Ltd
All →Sudarshan Pharma Industries Board Meeting Date
Sudarshan Pharma's board meets 29 October 2026 to consider Q2 results and a fund-raising proposal. Trading window remains closed until 48 hours after results.
Sudarshan Pharma Industries SME to Main Board Migration
Sudarshan Pharma's shares will list on NSE's main board from October 27, 2026, migrating from BSE SME. Trading begins under symbol SUDARSHAN, marking a platform upgrade.
Sudarshan Pharma Industries Other Announcement
Sudarshan Pharma Industries Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Sudarshan Pharma Industries Merger & Restructuring
Sudarshan Pharma terminated its proposal to acquire 9.50% of Med Therapy Biotechnology Inc. The promoters' parallel 1.50% each acquisition plan also stands terminated.
Sudarshan Pharma Industries Merger & Restructuring Worth ₹1.4 Cr
Sudarshan Pharma Industries completed the sale of its 51% stake in subsidiary Ishwari Healthcare Private Limited for ₹1.40 Crore. The entity ceases to be a subsidiary.
- Value
- ₹1.40 Cr
Sudarshan Pharma Industries Annual General Meeting
Sudarshan Pharma Industries Ltd held its 18th Annual General Meeting on September 22, 2026. The meeting covered the adoption of financial statements and director re-appointment.